Life sciences and biopharma hedge fund firms ramped up their venture capital activity in the first quarter, after most of them sharply pulled back in the three months ending in December.
Even so, the number of private investments is still way behind the pace set during the first three quarters of 2021, when the IPO market was red hot.
